APUS Apimeds Pharmaceuticals US, Inc.

Fundamentals / CIK 0001894525 / USD

Apimeds Pharmaceuticals US, Inc. reported $153.5M in total assets and a net loss of $22.74M through December 31, 2025 from SEC EDGAR filings.

Audited annual (10-K / 20-F) and quarterly (10-Q) statements parsed directly from SEC EDGAR CompanyFacts. Open APUS in the Convexity terminal for live prices, valuation multiples, transcripts, and insider flow.

Annual revenue and net income

3 fiscal years (2023 to 2025), reported in USD.

$0$0$0-$5.61MFY 2023 Net Income: -$778K2023FY 2024 Net Income: -$1.39M2024FY 2025 Net Income: -$6.00M2025

Financial statements and ratios

Reported in USD. Per-share figures and share counts are adjusted for stock splits from SEC filings.

Income Statement (Annual) · Reported in USD · Newest filing period first.

Income Statement Dec 31 Dec 31 Dec 31
Research & Development $1.63M -- $99K
Total Operating Expenses $11.91M $1.28M --
Operating Income -$11.91M -$1.28M -$747K
EBITDA -$11.91M -- --
Interest Income $108K $2.8K $7.8K
Interest Expense $283K $118K $38K
Net Income -$6.00M -$1.39M -$778K
Basic EPS -$5.50 -$1.80 -$1.70
Diluted EPS -$5.50 -$1.80 -$1.70
Basic Shares Outstanding 1.1M 790.4K 459.8K
Diluted Shares Outstanding 1.1M 790.4K --

Income Statement (Quarterly) · Reported in USD · Newest filing period first.

Income Statement 2026-09-30 2026-06-30 2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31
Revenue $2.90M $283K -- -- -- -- -- --
Cost of Revenue $54K -- -- -- -- -- -- --
Gross Profit $2.84M -- -- -- -- -- -- --
Research & Development -- $960K $901K -- $620K $652K -- --
Total Operating Expenses -- $6.28M $12.19M $7.04M $1.84M $2.66M $364K --
Operating Income $2.03M -$6.28M -$12.19M -$7.04M -$1.84M -$2.66M -$364K -$276K
EBITDA -- -$6.27M -$12.17M -- -- -$2.66M -- --
Interest Income -$22K $22K $7 $36K $56K $15K $3 $30
Interest Expense $1.09M $3.22M $859K $216K $6.3K $23K $38K $36K
Net Income $33.65M -$20.17M -$35.06M -$1.16M -$1.78M -$2.66M -$402K -$312K
Basic EPS $19.13 -$11.77 -$22.60 -- -$1.42 -$2.57 -$0.50 --
Diluted EPS $7.68 -$11.77 -$22.60 -- -$1.42 -$2.57 -$0.50 --
Basic Shares Outstanding 1.8M 1.7M 1.6M -- 1.3M 1.0M 790.4K --
Diluted Shares Outstanding 4.5M 1.7M 1.6M -- 1.3M 1.0M 790.4K --

Balance Sheet (Annual) · Reported in USD · Newest filing period first.

Balance Sheet Dec 31 Dec 31 Dec 31
Cash & Cash Equivalents $145K $3.5K $410K
Short-Term Investments $2.00M -- --
Cash & Short-Term Investments $2.14M $3.5K $410K
Other Current Assets $48K -- --
Total Current Assets $13.98M $13K $422K
Property, Plant & Equipment, Net $52K -- --
Total Non-Current Assets $150.2M $0 $0
Total Assets $164.2M $13K $422K
Accounts Payable $424K -- --
Total Current Liabilities $10.71M $1.02M $123K
Total Non-Current Liabilities $129K $347K $267K
Total Liabilities $10.84M $1.37M $390K
Total Debt (incl. Leases) $169K -- --
Common Stock $1.3K $79K $79K
Retained Earnings -$10.39M -$4.39M -$3.00M
Total Stockholders' Equity $153.3M -$1.36M $32K
Total Equity $153.3M -$1.36M $32K

Balance Sheet (Quarterly) · Reported in USD · Newest filing period first.

Balance Sheet 2026-09-30 2026-06-30 2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31
Cash & Cash Equivalents $18K $278K $980K $145K $6.99M $8.74M $250K $3.5K
Short-Term Investments -- -- $1.50M $2.00M -- -- -- --
Cash & Short-Term Investments $18K $278K $2.48M $2.14M $6.99M $8.74M $250K $3.5K
Accounts Receivable, Net $2.48M -- -- -- -- -- -- --
Other Current Assets $78K $49K $48K $48K -- -- -- --
Total Current Assets $10.85M $10.68M $13.15M $13.98M $9.09M $10.35M $260K $13K
Property, Plant & Equipment, Net -- $52K $57K $52K $34K $13K -- --
Total Non-Current Assets $142.7M $116.9M $128.1M $150.2M $164K $197K $0 $0
Total Assets $153.5M $127.6M $141.2M $164.2M $9.25M $10.55M $260K $13K
Accounts Payable $1.35M $2.09M -- $424K -- -- -- --
Deferred Revenue (Current) $278K -- -- -- -- -- -- --
Total Current Liabilities $13.01M $21.07M $14.58M $10.71M $1.09M $809K $1.77M $1.02M
Total Non-Current Liabilities $0 $102K $119K $129K $0 $0 $250K $347K
Total Liabilities $13.01M $21.18M $14.70M $10.84M $1.09M $809K $2.02M $1.37M
Total Debt (incl. Leases) -- $161K $171K $169K -- -- -- --
Common Stock $1.8K $1.5K $126K $1.3K $126K $126K $79K $79K
Retained Earnings -$31.98M -$65.63M -$45.45M -$10.39M -$9.24M -$7.46M -$4.79M -$4.39M
Total Stockholders' Equity $140.5M $106.4M $126.5M $153.3M $8.16M $9.74M -$1.76M -$1.36M
Total Equity $140.5M $106.4M $126.5M $153.3M $8.16M $9.74M -$1.76M -$1.36M

Cash Flow Statement (Annual) · Reported in USD · Newest filing period first.

Cash Flow Statement Dec 31 Dec 31 Dec 31
Net Income -$6.00M -$1.39M -$778K
Depreciation & Amortization $5.7K -- --
Stock-Based Compensation $1.57M $70K $70K
Operating Cash Flow -$8.93M -$734K -$628K
Capital Expenditure -$57K -- --
Free Cash Flow -$8.98M -- --
Acquisitions, Net $15K -- --
Investing Cash Flow -$10.06M -- --
Common Stock Issued $11.63M -- $1.05M
Financing Cash Flow $20.62M $326K $1.03M
Net Change in Cash $1.63M -$407K $404K

Cash Flow Statement (Quarterly) · Reported in USD · Newest filing period first.

Cash Flow Statement 2026-09-30 2026-06-30 2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31
Net Income $33.65M -$20.17M -$35.06M -$1.16M -$1.78M -$2.66M -$402K -$312K
Depreciation & Amortization -- $4.7K $20K -- -- $232 -- --
Stock-Based Compensation -- $105K -- $109K $1.74M $192K $0 --
Operating Cash Flow -$219K -$5.67M -$2.07M -$3.82M -$1.73M -$3.36M -$20K -$100K
Capital Expenditure $0 $0 -$9.4K -- -- -- -- --
Free Cash Flow -$219K -$5.67M -$2.08M -- -- -- -- --
Investing Cash Flow -$53K $1.50M $491K -- -- -- -- --
Financing Cash Flow $11K $3.47M $920K $8.49M $0 $11.86M $267K --
Net Change in Cash -$260K -$701K -$657K -$5.35M -$1.75M $8.48M $247K -$23K

Margins, returns, leverage, liquidity, and year-over-year growth computed directly from SEC EDGAR statement levels. Multi-year figures show cumulative per-share growth.

Ratios & Growth Dec 31 Dec 31 Dec 31
Return on Equity (ROE) -3.9% -- -2440.3%
Return on Assets (ROA) -3.7% -10645.6% -184.3%
Current Ratio 1.31x 0.01x 3.42x
Quick Ratio 0.20x 0.00x 3.33x
Debt to Equity 0.00x -- --

Quarterly margins, ROE, and ROA use trailing-twelve-month (TTM) flows summed across four contiguous quarters. Growth rates are true year-over-year comparisons against the same quarter a year earlier.

Ratios & Growth 2026-09-30 2026-06-30 2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31
Return on Equity (ROE) -16.2% -54.6% -32.1% -3.9% -63.2% -38.1% -- --
Return on Assets (ROA) -14.8% -45.6% -28.8% -3.7% -55.8% -35.2% -575.6% -10645.6%
Current Ratio 0.83x 0.51x 0.90x 1.31x 8.34x 12.79x 0.15x 0.01x
Quick Ratio 0.19x 0.01x 0.17x 0.20x 6.41x 10.80x 0.14x 0.00x
Debt to Equity -- 0.00x 0.00x 0.00x -- -- -- --
Source: SEC EDGAR CompanyFacts (CIK 0001894525) · from December 31, 2023 Data through September 30, 2026 · synced Nov 21, 2026, 05:10 UTC · Open in terminal